Fentanyl by continuous subcutaneous infusion for the management of cancer pain: A retrospective study

Journal of Pain and Symptom Management

Volumn 16, Issue 5, 1998, Pages 323-326

  Watanabe, Sharon ^a   Pereira, Jose ^a   Hanson, John ^a   Bruera, Eduardo ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

Cancer pain; Fentanyl; Subcutaneous opioid

Indexed keywords

FENTANYL;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; MALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION; TRANSDERMAL DRUG ADMINISTRATION;

AGED; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NEOPLASMS; PAIN, INTRACTABLE; PALLIATIVE CARE; RETROSPECTIVE STUDIES;

EID: 0031730555     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00095-5     Document Type: Article

References (15)

1. Foley K. The treatment of cancer pain. N Engl J Med. 313:1985;84-95.
2. Galer B.S., Coyle N., Pasternak G.W. Individual variability in response to different opioids. report of five cases Pain. 53:1993;353-355.
3. de Stoutz N.D., Bruera E., Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 10(5):1995;378-384.
4. Mather L.E. Clinical pharmacokinetics of fentanyl and its new derivatives. Clin Pharma. 8:1983;422-446.
5. Fainsinger R.L., Bruera E. How should we use transdermal fentanyl (TF) for pain management in palliative care patients? J Palliat Care. 12(1):1996;48-53.
6. Payne R., Chandler S., Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anti-Cancer Drugs. 6(3):1995;50-53.
7. Paix A., Coleman A., Lees J., Grigson J., Brooksbank M., Throne D., Ashby M. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain. 63:1995;263-269.
8. Folstein M.F., Folstein S., McHugh P.R. "Mini-mental state" a practical method for grading the cognitive state of patients for the clinician J Psych Res. 12:1975;189-198.
9. Korte W., de Stoutz N., Morant R. Transdermal fentanyl should be titrated on a day-to-day basis in well-monitored patients with uncontrolled cancer pain. Support Care Cancer. 3:1995;355.
10. Brooks D. Day-to-day titration of transdermal fentanyl is unwise. Support Care Cancer. 3:1995;210.
11. Gourlay G.K., Kowalski S.R., Plummer J.L., Cherry D.A., Gaukroger P., Cousins M.J. The transdermal administration of fentanyl in the treatment of postoperative pain. pharmacokinetics and pharmacodynamic effects Pain. 37:1989;193-202.
12. Portenoy R.K., Southam M.A., Gupta S.K., Lapin J., Layman M., Intrurrisi C.E., Foley K.M. Transdermal fentanyl for cancer pain. repeated dose pharmacokinetics Anesth. 78:1993;36-43.
13. Moulin D.E., Kreeft J.H., Murray-Parsons N., Bouquillon A.I. Comparison of subcutaneous and intravenous hydrdomorphone infusions for management of cancer pain. Lancet. 337:1991;465-468.
14. Donner B., Zena M., Tryba M., Strumpf M. Direct conversion from oral morphine to transdermal fentanyl. a multicenter study in patients with cancer pain Pain. 64:1996;527-534.
15. Bruera E., Pereira J., Watanabe S., Belzile M., Kuehn N., Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer. 78(4):1996;852-857.